Display search results for ** instead (14 products)

Showing 1-10 of 14

This issue of Vital Signs, released on November 6, 2014, discusses Immucors collaboration with Sirona Genomics, Becton Dickinsons acquisition of GenCell Biosystems, and an update on the Ebola virus.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on December 5, 2014, discusses LabCorps acquisition of Covance, MedImmunes acquisition of Definiens, the Google X cancer and heart attack detector, and VWRs acquisition of two fluid handling components companies.

USD 500.00

USD 375.00 save 25 %

Overview and discussion of the top themes from the RSNA 2014 Annual Meeting, with a focus on the vendor Exhibit Floor.

USD 500.00

USD 375.00 save 25 %

In early November 2013, Frost & Sullivan conducted an online survey, followed up by a live focus group with about 20 C-suite executives from leading commercial payer organizations across the US. The goal was to gain insights into how the health insurance industry is approaching the use of analytics solutions going into 2014. Analytics solutions we...

USD 450.00

USD 337.50 save 25 %

Healthcare systems across the globe are facing rising operation costs, shortage of skilled labor and budgetary restraints, which has resulted in reduction in efficiency and quality of care. An increasing aging population, need for chronic disease management and providing access to healthcare for the geographically fragmented population demands the ...

USD 450.00

USD 337.50 save 25 %

As the Wearables sector continues to explode in interest in the healthcare space in terms of potential hard benefit to consumers, providers, and vendors across the value chain of connected healthcare, areas are expanding in launches besides that of activity tracking. The following Vital Signs presents analyst discussion regarding brain wearables in...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.

USD 450.00

USD 337.50 save 25 %

The wearables market is currently a center of hype and interest across the varied landscape of consumers, vendors, providers, payers, and other stakeholders interested in the broader digital health market. Companies are trying to better understand consumer habits, exploring device monetization outside of the early adopting fitness crowd, increasing...

USD 450.00

USD 337.50 save 25 %

Showing 1-10 of 14